CCC
MEDP icon

Crescent Capital Consulting’s Medpace MEDP Stock Holding History

Crescent Capital Consulting’s Portfolio MEDP Stock Details MEDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$4K Hold
18
– – ﹤0.01% 446
2021
Q3 		$3K Buy
+18
New +$3.28K ﹤0.01% 485

Other funds holding MEDP

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ESCM
Echo Street Capital Management New York $747M AUM 24.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return

Crescent Capital Consulting's MEDP Position: Q4 2021 in Review

Crescent Capital Consulting held its Medpace (MEDP) position steady in Q4 2021 at 18 shares worth $4K. The position accounts for ﹤0.01% of the portfolio, ranked #446.

Crescent Capital Consulting first reported a position in MEDP in Q3 2021 and has held it in 2 quarters since. 386 funds tracked by Wall St. Rank hold MEDP as of Q4 2021.

  • Crescent Capital Consulting held 18 shares of Medpace worth $4K as of Q4 2021.
  • Crescent Capital Consulting left its Medpace share count unchanged in Q4 2021.
  • Medpace made up ﹤0.01% of Crescent Capital Consulting's portfolio in Q4 2021, its #446 holding.
  • Crescent Capital Consulting first reported a position in Medpace in Q3 2021 and has held it in 2 quarters since.
  • 386 funds tracked by Wall St. Rank held Medpace as of Q4 2021.

Based on Crescent Capital Consulting's 13F filing for Q4 2021, filed 18 Jan 2022.